



CALIFORNIA
ACCESS COALITION

In partnership with Janssen Pharmaceutical Companies
of Johnson & Johnson

Webinar:

The Utility of Long Acting Medications During COVID-19 and Beyond

August 10, 2020 | 10:00 AM – 12:00 PM

[Via Zoom](#)

About the webinar:

This webinar will highlight the utility of long acting medications (LAMs) with leading experts in the field including representatives from: Substance Abuse and Mental Health Services Administration (SAMHSA), National Council for Behavioral Health (NCBH), National Alliance on Mental Illness (NAMI), and CAC Corporate Partners' physician and researcher representatives. Attendees will learn how LAMs can serve as an optimal treatment modality for a variety of disorders during and beyond the COVID-19 pandemic.

Program:

Opening Remarks:

Le Ondra Clark Harvey, Ph.D., *CAC Executive Director*

Welcome Remarks:

Assemblymember Dr. Joaquin Arambula

Panel Discussion: *The Utility of LAMs During COVID-19 and Beyond*

Moderator: Le Ondra Clark Harvey, Ph.D., *CAC Executive Director*

Panelists and Presentations:

Patient Perspective: A Family's Journey to the Other Side of a Schizophrenia Diagnosis

- Maye Hayes Jepson, Family Mental Health Advocate

Innovations and Voices from the Bench

- Wayne C. Drevets, M.D, Scientific Vice President, Janssen Pharmaceuticals Research & Development, LLC
- Hiten Patadia, PharmD, Managed Markets Liaison – West, Otsuka Pharmaceutical Cos.

National Guidance

- Anita Everett, M.D., DFAPA, Director of Center for Mental Health Services, SAMHSA
- Joe Parks, MD, Vice President, Practice Improvement & Medical Director, NCBH

Patient Perspective

- Andrew Sperling, Director of Legislative Advocacy, NAMI

Q&A

Closing Remarks & Adjournment

Thank you to the following Corporate Partner for making this event possible!

